| Autor: |
Ergin, Mehmet, Özkan, Metin, Ergin, Meral Ilgaz, Cephe, Ahu |
| Předmět: |
|
| Zdroj: |
Journal of Clinical Practice & Research; Mar2023, Vol. 45 Issue 2, p165-171, 7p |
| Abstrakt: |
Objective: This study aimed to examine the mutation panel studied with liquid biopsy in patients diagnosed with lung adenocancer and to investigate its relationship with survival. Materials and Methods: The study comprised 24 patients diagnosed with lung adenocarcinoma between the ages of 18 and 80 who were metastatic and had not yet received treatment. Using the next-generation sequencing commercial kit 56G Oncology Panel, the cfDNAs (cell-free DNAs) isolated from the patient's blood were analyzed. SOPHiA DDM® (Saint-Sulpice, Switzerland) bioinformatics program was used to classify the detected genetic variants. The patients were followed for 3 years in terms of survival. For the statistical analysis, R Version 4.1.3 (https://rstudio.com/) and TURCOSA Analytical (https://turcosa.com.tr/) software was used. Results: Mutation was found in liquid biopsy in 16 (66.7%) of the patients, and more than one mutation was detected in seven (29.1%) patients. The relationship between the variables and mortality was examined in the cases included in the study; there was a significant relationship between age and mortality (p=0.029), and mortality was increasing with aging. In the survival analysis, no statistically significant relationship was found between gender, smoking status, mutation status, and survival according to Kaplan--Meier graphs and log-rank tests. Conclusion: Therefore, driver mutation was detected in 66.7% of the patients. Liquid biopsy may be essential in the progression of lung adenocarcinoma to detect the driver mutations, which are targets for treatments. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
